RxDoctor Payments Data

Frederick Lee, MD

Endocrinology, Diabetes & Metabolism · Pasadena, CANPI 1063508679

Payments from drug & device makers

$2,684in general payments, 2019–2025

Across 118 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$691
  • Lilly USA, LLC$331
  • Abbott$305
  • AstraZeneca$231
  • Dexcom, Inc.$200
  • Novo Nordisk$189
  • plus $738 from 14 others

What the payments were for

  • Food & beverage$2,684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,684 in reported general payments places this provider in the 55th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$75,761
Medicare patients
192
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin295$295,590
TrulicityDulaglutide142$207,375
OzempicSemaglutide153$178,360
FarxigaDapagliflozin Propanediol72$84,507
ProliaDenosumab45$76,526
JanuviaSitagliptin Phosphate37$44,001
MounjaroTirzepatide20$30,971
KerendiaFinerenone28$24,230
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog44$23,001
XareltoRivaroxaban33$20,455
EliquisApixaban24$18,896
Humalog Kwikpen U-100Insulin Lispro55$9,453
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$7,569
SynthroidLevothyroxine Sodium68$7,324
Lantus SolostarInsulin Glargine,hum.Rec.Anlog85$6,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$169$301,213306 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$331$241,357182 claims
Novo NordiskOzempic$189$178,360153 claims
AstraZenecaFarxiga$231$84,50772 claims
AmgenProlia$112$76,52645 claims
BayerKerendia$691$24,23028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →